总部位于纽约的 Synchron 收购了 Acquandas 的少数股权，以改善美国试验中的脑植入设备 Synchron Switch 的制造。 New York-based Synchron acquires minority stake in Acquandas for improving manufacturing of brain implant device Synchron Switch in US trial.

总部位于纽约的 Synchron 是埃隆·马斯克 (Elon Musk) 旗下 Neuralink 的竞争对手，该公司已收购医疗组件制造商 Acquandas 的少数股权，以改善其制造业务。 Synchron, a New York-based competitor to Elon Musk's Neuralink, has acquired a minority equity stake in medical component maker Acquandas to improve its manufacturing operations. Synchron 的大脑植入设备 Synchron Switch 目前正在美国进行一项针对严重瘫痪患者的小型试验。 Synchron's brain implant device, the Synchron Switch, is currently in a small US trial involving patients with severe paralysis. 该公司于 2021 年 7 月获得美国批准进行人体测试。 The company received US approval for human testing in July 2021. Synchron 尚未透露所收购股份的规模或协议的财务细节。 Synchron has not disclosed the size of the stake acquired or financial details of the agreement.